Pfizer Launches Global Centers for Therapeutic Innovation

Pfizer Inc.Pfizer Inc. (NYSE: PFE) announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers. The University of California, San Francisco is the first collaboration in the network.

"The Centers for Therapeutic Innovation represents a truly novel open innovation paradigm, combining the unique advantages of top academic research institutions with Pfizer's leading drug development capabilities and research technologies," said Mikael Dolsten, M.D., Ph.D., president of Pfizer Worldwide Research & Development. "This new way of engaging leading external scientists is a key component of our R&D strategy. We are excited to pioneer this approach to seek to translate science into novel proofs of mechanism in a more efficient and accelerated manner to better serve patients," Dr. Dolsten said.

Anthony Coyle, Ph.D., will head Pfizer's Global Centers for Therapeutic Innovation, headquartered in Cambridge, Mass. Dr. Coyle brings extensive knowledge of the full drug development process to this initiative. As former Vice President and Global Head of Respiratory, Inflammation, and Autoimmune Research at MedImmune Biologics, a division of AstraZeneca, he advanced research and the clinical biologics pipeline.

"With his keen sense of biotechnology culture, strong scientific leadership and history of building successful collaborations, Anthony Coyle is the ideal person to lead the Centers for Therapeutic Innovation," said Jose-Carlos Gutierrez-Ramos, Ph.D., Pfizer's senior vice president of Worldwide BioTherapeutics Research and Development. "This new model complements the venture capitalist - funded biotech start up and has the potential to catalyze the transformation of global biomedical drug discovery by advancing scientific breakthroughs in translational medicine."

A key aspect of the Centers for Therapeutic Innovation is Pfizer's commitment to establish local Centers at each partner site that enable Pfizer and academic medical center teams to work side by side. Pfizer will also make available its proprietary antibody libraries and advanced research tools along with technical support across the development process. In addition to funding pre-clinical and clinical development programs, Pfizer will offer its partners equitable intellectual property and ownership rights to support continued experimentation and exploration, as well as broad rights to publication. Milestone payments and royalties related to the advancement of sponsored programs will also be granted. In return, Pfizer will have the opportunity to potentially broaden its pipeline with novel and highly differentiated candidate drugs to treat diseases of high unmet medical need.

The Centers for Therapeutic Innovation will initially focus on collaborations within the U.S. and build the network at other U.S.-based medical institutions and is expected to expand into Europe and Asia in 2012. Each Center will be governed by a Joint Steering Committee comprised of Pfizer and academic medical center representatives who will provide leadership and evaluate the success of each program through discovery and early stage clinical development.

"This is an excellent example of how we can fundamentally improve the process of translating research into better drugs by bringing all of the people involved to the same table," said Jeffrey A. Bluestone, Ph.D., UCSF executive vice chancellor and provost, and the A.W. and Mary Margaret Clausen Distinguished Professor in Metabolism and Endocrinology at UCSF. "This partnership takes advantage of the expertise in both camps to create new ways to develop drugs that have the potential to achieve their most important goal - improving patient health."

"UCSF is a world-class academic medical center with a strong focus on both basic science and clinical research, which is why Pfizer is partnering with them on this initiative. Ultimately, we believe this could create significant benefit for the patient, for investigators, and for each institution," said Dr. Gutierrez-Ramos.

About the University of California, San Francisco
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. For further information, visit www.ucsf.edu.

Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...